Last news
AXA's Title-Sponsored "The 31st Green Power Hike" Successfully Completed

AXA's Title-Sponsored "The 31st Green Power Hike" Successfully Completed

Promoting the "Leave No Trace" message to create a greener future HONG KONG, Jan. 24, 2024 /PRNewswire/ -- The 31st Green Power Hike, organised by Green Power with AXA as the Title Sponsor for the first time, successfully took place on 13 January....

WuXi XDC and Celltrion Sign MOU for Integrated Services for Antibody-Drug Conjugates (ADCs)

WuXi XDC and Celltrion Sign MOU for Integrated Services for Antibody-Drug Conjugates (ADCs)

SHANGHAI and INCHEON, South Korea, Jan. 24, 2024 /PRNewswire/ -- WuXi XDC(2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on ADC and the other types of bioconjugate market, and Celltrion, Inc....

SUMSEI Triumphs at CES 2024, Solidifying Its Position as a Premier Home Appliance Brand Redefining the Intersection of Nature and Technology

SUMSEI Triumphs at CES 2024, Solidifying Its Position as a Premier Home Appliance Brand Redefining the Intersection of Nature and Technology

Sensory Engagement: An Immersive Experiential Booth Articulating the Brand Philosophy of 'Nature, Anytime Anywhere' Earning High Acclaim and Positive Reception for 'Air Shower,' a Pioneering Product in a New Category, and 'In the Forest' SEOUL,...

"Home in Shenyang is Great": Shenyang, China, is building a high-standard public service system for foreigners

"Home in Shenyang is Great": Shenyang, China, is building a high-standard public service system for foreigners

SHENYANG, China, Jan. 24, 2024 /PRNewswire/ -- A news report from CRI Online: "Shenyang is now more internationalized, with the construction of international hospitals, international schools and better infrastructure. Both foreigners and local...

PharmAbcine Announces First Patient Dosed in Phase 1a/b Clinical Trial of PMC-309 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced or Metastatic Solid Tumors

PharmAbcine Announces First Patient Dosed in Phase 1a/b Clinical Trial of PMC-309 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced or Metastatic Solid Tumors

Initiation of Phase 1a/b clinical trial exploring MTD, RP2D, safety and tolerability of PMC-309 monotherapy and combination therapy with KEYTRUDA® The clinical trial aims to enroll a total of 67 patients across four institutions in Australia...

Veritas Application Mobility Service Takes Cloud Adoption Time from Months to Minutes

Veritas Application Mobility Service Takes Cloud Adoption Time from Months to Minutes

Availability expanded beyond current customers and now includes support for Microsoft Azure SINGAPORE, Jan. 24, 2024 /PRNewswire/ -- Veritas Technologies, the leader in secure multi-cloud data management, is making it easier for enterprises to...

INTREPID Alliance Releases Review of Antiviral Compounds in Clinical Development to Contribute to Collaborative Efforts in Pandemic Preparedness

INTREPID Alliance Releases Review of Antiviral Compounds in Clinical Development to Contribute to Collaborative Efforts in Pandemic Preparedness

Global landscape analysis identifies strengths and gaps in R&D pipeline to inform international pandemic preparedness efforts ROME and CAMBRIDGE, Mass., Jan. 24, 2024 /PRNewswire/ -- The INTREPID Alliance, a consortium of innovative...

J.S. Held Global Risk Report Reveals Business Opportunities Amid Uncertainty

J.S. Held Global Risk Report Reveals Business Opportunities Amid Uncertainty

The J.S. Held Global Risk Report presents actionable insights that support strategic business decision-making. JERICHO, N.Y., Jan. 24, 2024 /PRNewswire/ -- Global consulting firm J.S. Held introduces the 2024 Global Risk Report against the backdrop...

menu
menu